Crossmark

A Response to: Letter to the Editor Regarding “Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain”

Crossref DOI link: https://doi.org/10.1007/s40487-026-00421-2

Published Online: 2026-02-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lozano, Virginia

Llinares, Julia

Halavacek, Patrick

Ashman, Olivia

Carcedo, David https://orcid.org/0000-0002-2809-7399
Encinas, Cristina

Martínez-López, Joaquín
License Information

Text and Data Mining valid from 2026-02-27

Version of Record valid from 2026-02-27
More Information

Article History

Received: 2 December 2025

Accepted: 4 February 2026

First Online: 27 February 2026

Declarations

:

: Virginia Lozano, Julia Llinares, Patrick Hlavacek and Olivia Ashman are employees of Pfizer and may hold Pfizer stock. David Carcedo is employee of Hygeia Consulting. Joaquín Martínez-López has received honoraria derived from research projects from Amgen, Incity, Janssen and Pfizer, and from lectures and participation in advisory boards from Amgen, BMS, Gilead, Incity, Janssen, Novartis, Pfizer and Roche. Cristina Encinas has received honoraria derived from lectures and participation in advisory boards from Amgen, BMS, GSK, Johnson and Johnson, Menarini Stemline, Sanofi and Pfizer.

: This response letter is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below